Rafal R. Sicinski;Hector F. DeLuca;Rafal Barycki;Margaret Clagett-Dame;Katarzyna Plonska-Ocypa;Lori A. Plum;Izabela Sibliska;Katarzyna M. Barycka
发明人:
Hector F. DeLuca,Izabela Sibliska,Lori A. Plum,Margaret Clagett-Dame,Rafal R. Sicinski,Katarzyna M. Barycka,Katarzyna Plonska-Ocypa,Rafal Barycki
申请号：
US13278846
公开号：
US08518917B2
申请日:
2011.10.21
申请国别(地区):
US
年份:
2013
代理人:
摘要：
This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D3 and (20R)-25-hydroxy-2-methylene-19-nor-vitamin D3, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. Although these compounds have relatively low calcemic activities they may also be useful in the treatment of bone diseases due to their ability to act as prodrugs in vivo.
